YS Biopharma Co Ltd
NASDAQ:LSB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ami Organics Ltd
NSE:AMIORG
|
IN |
|
Duckhorn Portfolio Inc
NYSE:NAPA
|
US |
YS Biopharma Co Ltd
Other Current Liabilities
YS Biopharma Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
YS Biopharma Co Ltd
NASDAQ:LSB
|
Other Current Liabilities
¥109.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Other Current Liabilities
¥1.8B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Other Current Liabilities
¥7.1B
|
CAGR 3-Years
112%
|
CAGR 5-Years
92%
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Other Current Liabilities
¥718.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Other Current Liabilities
¥1.2B
|
CAGR 3-Years
35%
|
CAGR 5-Years
189%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Other Current Liabilities
¥535.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
YS Biopharma Co Ltd
Glance View
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
See Also
What is YS Biopharma Co Ltd's Other Current Liabilities?
Other Current Liabilities
109.3m
CNY
Based on the financial report for Mar 31, 2025, YS Biopharma Co Ltd's Other Current Liabilities amounts to 109.3m CNY.
What is YS Biopharma Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
1%
Over the last year, the Other Current Liabilities growth was -19%. The average annual Other Current Liabilities growth rates for YS Biopharma Co Ltd have been 1% over the past three years .
